NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® ...
Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
Findings showed Zepzelca with atezolizumab reduced the risk of disease progression or death by 46% and the risk of death by 27% vs atezolizumab alone. The approval was based on data from the ...
Adding tucatinib to standard first-line maintenance therapy in patients with HER2-positive metastatic breast cancer led to a clinically meaningful delay in disease progression, regardless of the ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in ...
The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...
At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and ...
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results